Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray is a multi-component peptide research preparation supplied in a liquid spray format for controlled laboratory investigation.
The formulation combines Ipamorelin, a synthetic peptide associated experimentally with GHS-R1a/ghrelin receptor research, with CJC-1295 No DAC-labelled GHRH-related research material relevant to GHRHR and GPCR studies.
Suitable research areas include peptide-receptor biology, comparative molecular pharmacology, formulation investigation, peptide stability and analytical characterisation.
The 10mg designation represents the stated total research quantity and is not a dosage recommendation. Exact component amounts or ratios should be confirmed from product-specific documentation.
For Research Use Only – Not for human or veterinary consumption or administration.
Original price was: $121.85.$108.31Current price is: $108.31.
Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray from Axion Peptide Lab is a multi-component peptide research preparation supplied in a convenient liquid spray format for controlled laboratory, molecular and analytical investigation.
This research blend combines two distinct peptide materials: Ipamorelin, a synthetic growth hormone secretagogue associated in experimental literature with the growth hormone secretagogue receptor, commonly known as GHS-R1a or the ghrelin receptor; and CJC-1295 No DAC, commercial terminology commonly associated with a short-acting GHRH-related research peptide.
Combining these materials within a single research preparation can support appropriately designed comparative experiments involving peptide-receptor biology, GPCR signalling, molecular pharmacology, formulation behaviour and analytical characterisation.
The 10mg designation identifies the stated total research quantity associated with the product and is not a dosage recommendation. Researchers should consult product-specific documentation to confirm the precise amount and ratio of each component.
“Nasal Spray” describes the research presentation only and does not represent a recommendation or instruction for human intranasal administration.
For Research Use Only – Not for human or veterinary consumption or administration.
Ipamorelin is a synthetic pentapeptide originally investigated as a growth hormone secretagogue.
Its structure contains five amino-acid or amino-acid-derived residues and has been described in scientific literature by the sequence:
Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Ipamorelin has been studied experimentally for its interaction with the growth hormone secretagogue receptor type 1a, abbreviated GHS-R1a.
GHS-R1a is also widely known as the ghrelin receptor and belongs to the G protein-coupled receptor, or GPCR, superfamily.
These characteristics make Ipamorelin relevant to controlled experiments involving ligand-receptor interactions, receptor pharmacology, GPCR signalling and synthetic peptide structure-function relationships. Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray
CJC-1295 No DAC is terminology used commercially for GHRH-related research material without the Drug Affinity Complex functionality associated with long-acting CJC-1295.
The terminology requires some scientific care.
Published studies involving original CJC-1295 frequently concern the DAC-containing molecule. Commercial materials marketed as “CJC-1295 No DAC” are often associated with Modified GRF(1-29)-type research peptides.
Researchers should therefore verify the exact molecular identity and sequence of their material using product-specific or batch-specific documentation rather than assuming that data generated with CJC-1295 With DAC automatically apply to No DAC material.
CJC-1295 No DAC-related materials are commonly investigated in experimental systems involving the growth hormone-releasing hormone receptor, or GHRHR.
GHRHR is another member of the GPCR family. Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray
One of the scientifically interesting characteristics of this blend is that its components are associated with distinct receptor systems.
Ipamorelin is associated with GHS-R1a, while GHRH-related peptides are investigated in relation to GHRHR.
This makes the combination relevant to laboratory experiments examining different peptide-receptor pathways within the same controlled research design.
Researchers may investigate each component independently before comparing results with those obtained from the combined preparation.
This approach can help distinguish individual peptide characteristics from observations associated with a multi-component formulation.
It is important not to assume that combining the peptides automatically produces a particular biological outcome.
Experimental conclusions should be based on measured data. Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray
Both receptor systems associated with these research peptides belong to the broad GPCR superfamily.
GPCRs are membrane proteins that respond to extracellular ligands and transmit information through intracellular signalling pathways.
They represent one of the most extensively investigated receptor classes in molecular pharmacology.
Research involving this blend may therefore contribute to controlled investigation of receptor activation, signalling dynamics, ligand selectivity and comparative peptide pharmacology.
The specific methods and endpoints used should be appropriate to the laboratory model being studied. Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray
Ipamorelin and CJC-1295 No DAC-related materials differ substantially in peptide structure.
Ipamorelin is a compact synthetic pentapeptide, while the GHRH-related component is a longer peptide sequence.
This difference provides opportunities for comparative peptide research.
Scientists can examine how sequence length, amino-acid substitutions and structural modifications influence properties such as receptor interaction, analytical behaviour or stability.
Researchers may also compare the blend with individually prepared controls to evaluate how each component behaves under identical experimental conditions. Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray
Multi-component peptide preparations present additional analytical challenges compared with single-component materials.
Researchers may need to identify and quantify two separate peptide components within the same sample.
Analytical techniques appropriate to peptide research can include high-performance liquid chromatography, mass spectrometry and other validated laboratory methods.
Chromatographic separation can help distinguish individual components, while mass-spectrometric techniques may support molecular identity investigation.
Analytical methodology should be validated according to the requirements of the specific experiment.
Batch-specific documentation should be consulted where precise composition or purity specifications are required. Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray
The liquid spray presentation may be useful in controlled formulation experiments.
Researchers can investigate variables such as peptide compatibility, solution stability, analytical recovery and interactions between multiple peptide components in a shared formulation environment.
Multi-component formulations may behave differently from individual peptide solutions.
For this reason, conclusions regarding stability or compatibility should not simply be transferred from single-component studies.
The exact formulation, solvent system and excipients should be confirmed from product-specific documentation when these variables are relevant to experimental interpretation. Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray
Peptide stability can be affected by numerous environmental factors.
Researchers may investigate how time, temperature, pH, light exposure and formulation conditions influence individual components of a peptide blend.
Analytical monitoring can help identify changes in chromatographic profiles or other measurable characteristics.
A blend also creates an opportunity to study whether the presence of one component influences the analytical stability of another.
Product-specific storage requirements should always be taken from verified documentation rather than assumed from generic peptide recommendations.
Ipamorelin and GHRH-related research peptides have historically been investigated within molecular pharmacology.
Controlled experiments can examine receptor interaction, signalling pathways, concentration-response relationships and comparative ligand behaviour.
When studying a combination, appropriate controls are particularly important.
Experiments may include the individual components, the combined preparation and relevant negative or reference controls.
This approach can provide more informative data than evaluating the blend in isolation.
Research findings should not be converted into claims of established therapeutic effectiveness.
The 10mg designation identifies the stated research quantity associated with this product.
For a blend, total quantity alone does not establish how much of each individual peptide is present.
Researchers requiring exact quantitative composition should consult the applicable product specification or batch documentation.
For example, an equal-ratio blend should only be described as such if that ratio is confirmed for the actual product.
The 10mg label must not be interpreted as a human dosage recommendation.
Experimental quantities should instead be determined through validated laboratory protocols. Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray
The term Nasal Spray describes the physical presentation of this research product.
A spray dispenser can provide a defined liquid-delivery format useful for formulation, device or analytical studies.
However, packaging a peptide research blend in this format does not establish that intranasal administration is clinically validated, approved or appropriate for personal use.
Axion Peptide Lab supplies the preparation exclusively for legitimate research applications and does not provide human administration protocols. Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray
The Ipamorelin + CJC-1295 No DAC research blend may be relevant to controlled studies involving:
These are research categories rather than medical indications.
Reproducibility requires accurate documentation of the materials used in an experiment.
Researchers should record the product identity, batch information, composition, experimental conditions and analytical methodology.
For multi-component preparations, the verified amount or ratio of each component can be particularly important.
Where available, batch-specific documentation should be reviewed before quantitative experiments are conducted.
Certificate of Analysis and independent testing availability may vary according to product and batch.
Exact purity, sterility, concentration, component ratio or other specifications should only be claimed where supported by appropriate documentation. Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray
Researchers looking to buy Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray can source this multi-component research preparation from Axion Peptide Lab for legitimate scientific, analytical and laboratory investigation.
Its combination of a GHS-R1a-associated secretagogue and a GHRH-related research peptide provides an interesting platform for comparative receptor, GPCR, formulation and analytical studies.
Researchers should verify the precise composition and specifications of the preparation against applicable product documentation before incorporating it into quantitative experimental workflows.
For Research Use Only – Not for human or veterinary consumption or administration.
It is a multi-component research preparation combining Ipamorelin with a CJC-1295 No DAC-labelled GHRH-related peptide material for controlled laboratory investigation.
Ipamorelin has been experimentally associated with GHS-R1a, commonly called the ghrelin receptor, which belongs to the GPCR family.
CJC-1295 No DAC-related materials are commonly investigated in relation to the growth hormone-releasing hormone receptor, or GHRHR.
No. The No DAC terminology indicates material without the Drug Affinity Complex functionality. Researchers should not automatically transfer findings from DAC-containing CJC-1295 to No DAC material.
Not necessarily. The 10mg designation represents the stated total research quantity. The exact amount or ratio of each component should be verified from product-specific documentation.
Potential research areas include peptide-receptor biology, GHS-R1a and GHRHR investigation, GPCR signalling, molecular pharmacology, formulation research, stability and analytical characterisation.
A combined preparation can be used in appropriately controlled comparative experiments examining two distinct peptide-receptor systems, provided suitable individual-component controls are included.
Yes. Appropriate chromatographic, mass-spectrometric and other validated analytical techniques may be used to investigate component identity, composition and stability.
No. Nasal Spray describes the research presentation only. It does not constitute a recommendation or instruction for human intranasal use. Ipamorelin + CJC-1295 No DAC 10mg Nasal Spray
The research blend is available from Axion Peptide Lab for legitimate laboratory and analytical applications, subject to product availability and applicable requirements.
